Eye Length Signal With Myopia Control

Myopia Clinical Trial

Official title: A Prospective, Randomised, Dispensing Clinical Trial to Compare the Visual Performance, Wearability and Ocular Response of Myopia Control, Novel Myopia Control and Single Vision Spectacle Lenses

Status Recruiting

Clinical Trial Summary

Myopia, considered as a global epidemic, is rapidly rising in prevalence especially in east Asian countries. Younger ages are associated with greater annual progression and thus early onset myopia is likely to result in higher levels of final net myopia.[1] Myopia, especially high myopia (more than -6.00D) is associated vision threatening complications such as cataract, glaucoma, choroidal thinning, vitreous liquefaction, myopic maculopathy, retinal detachment etc. Furthermore, myopia can affect the quality of life of an individual through restriction of employment in certain fields such as aviation. Myopia also imposes economic burden through the recurring cost of vision correction such as spectacles, contact lenses and specialist consultation fee. It is therefore important to develop novel optical and pharmaceutical strategies that can control or slow the progression of myopia.

Clinical Trial Description

To date, the strategies used to control or slow the progression of myopia are optical and pharmaceutical methods. Among spectacles, bifocal spectacles with and without prism, progressive addition lenses, spectacles altering peripheral hyperopic defocus, spectacles imposing myopic defocus both centrally and peripherally and spectacles with multiple defocus segments that imposes myopic defocus in front, midperiphery and periphery of the retina (defocus incorporating multiple segments or DIMS) are used to reduce the progression[2-6]. Of these, spectacles designed to alter peripheral defocus demonstrated a small treatment effect in reducing myopia progression[6, 7]. Bifocal and progressive addition spectacles demonstrated variable treatment effect in reducing progression of myopia. Among contact lenses, multifocal contact lenses altering peripheral defocus, extended depth of focus contact lenses altering higher order aberrations in order to degrade the retinal image behind the retina have shown promising results in slowing myopia progression along with orthokeratology treatment[8-12]. Among these, orthokeratology and multifocal soft contact lenses (centre distance multifocal contact lenses) showed promising results in slowing myopia progression[9, 12].

Pharmaceutical interventions include Atropine, Pirenzepine, 7-Methylxanthine and Timolol[13].Atropine is the most widely used, with higher concentrations more effective. Atropine 1% concentration demonstrated 60 to 80% reduction in progression of myopia. However, ocular side effects such as blurred vision, photophobia etc associated with atropine makes it a less appealing option. Among the various treatment approaches, spectacles pose the least or minimal side effects compared to contact lenses, orthokeratology or pharmaceutical strategies. Therefore, this study aims to determine the effect of novel myopia control prototype spectacle design on wearability and physiological ocular response among myopic children aged 7 to 14 years. ;

Related Conditions & MeSH terms

• Myopia

• NCT number: NCT04813640
• Study type: Interventional
• Source: Brien Holden Vision Institute
• Contact: Minh Huy Tran, M.D., Msc.
• Phone: (+84) 907 110 892
• Email: huy.tran@haiyeneyecare.com
• Status: Recruiting
• Phase: N/A
• Start date: February 5, 2021
• Completion date: October 31, 2021